Desarrollo del escap-cdv como instrumento de medida para la valoración de la calidad de vida en el cáncer de próstata. primera parte
Leído
1597
Vecesse ha leído el artículo
940
Total PDF
657
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 8 | 8 |
| 2025 11 | 0 | 37 | 37 |
| 2025 10 | 0 | 15 | 15 |
| 2025 9 | 0 | 14 | 14 |
| 2025 8 | 0 | 9 | 9 |
| 2025 7 | 0 | 6 | 6 |
| 2025 6 | 0 | 4 | 4 |
| 2025 5 | 0 | 8 | 8 |
| 2025 4 | 0 | 4 | 4 |
| 2025 3 | 0 | 8 | 8 |
| 2025 2 | 0 | 8 | 8 |
| 2025 1 | 0 | 3 | 3 |
| 2024 12 | 0 | 2 | 2 |
| 2024 11 | 0 | 7 | 7 |
| 2024 10 | 0 | 8 | 8 |
| 2024 9 | 0 | 14 | 14 |
| 2024 8 | 0 | 3 | 3 |
| 2024 7 | 0 | 4 | 4 |
| 2024 6 | 0 | 8 | 8 |
| 2024 5 | 0 | 9 | 9 |
| 2024 4 | 0 | 8 | 8 |
| 2024 3 | 0 | 13 | 13 |
| 2024 2 | 0 | 1 | 1 |
| 2024 1 | 0 | 12 | 12 |
| 2023 12 | 0 | 16 | 16 |
| 2023 11 | 0 | 12 | 12 |
| 2023 10 | 0 | 30 | 30 |
| 2023 9 | 0 | 5 | 5 |
| 2023 8 | 0 | 7 | 7 |
| 2023 7 | 0 | 26 | 26 |
| 2023 6 | 0 | 10 | 10 |
| 2023 5 | 0 | 17 | 17 |
| 2023 4 | 0 | 8 | 8 |
| 2023 3 | 0 | 12 | 12 |
| 2023 2 | 0 | 10 | 10 |
| 2022 1 | 0 | 6 | 6 |
| 2022 12 | 0 | 10 | 10 |
| 2022 11 | 0 | 16 | 16 |
| 2022 10 | 0 | 10 | 10 |
| 2022 9 | 0 | 8 | 8 |
| 2022 8 | 0 | 3 | 3 |
| 2022 7 | 0 | 7 | 7 |
| 2022 6 | 0 | 4 | 4 |
| 2022 5 | 0 | 4 | 4 |
| 2022 4 | 0 | 6 | 6 |
| 2022 3 | 0 | 4 | 4 |
| 2022 2 | 0 | 1 | 1 |
| 2021 1 | 0 | 1 | 1 |
| 2021 12 | 0 | 5 | 5 |
| 2021 11 | 0 | 8 | 8 |
| 2021 10 | 0 | 1 | 1 |
| 2021 8 | 0 | 3 | 3 |
| 2021 7 | 0 | 2 | 2 |
| 2021 6 | 0 | 3 | 3 |
| 2021 5 | 0 | 2 | 2 |
| 2021 4 | 0 | 7 | 7 |
| 2021 3 | 0 | 6 | 6 |
| 2021 2 | 0 | 3 | 3 |
| 2020 1 | 0 | 6 | 6 |
| 2020 12 | 0 | 2 | 2 |
| 2020 11 | 0 | 4 | 4 |
| 2020 10 | 0 | 3 | 3 |
| 2020 9 | 0 | 10 | 10 |
| 2020 8 | 0 | 2 | 2 |
| 2020 6 | 0 | 1 | 1 |
| 2020 5 | 0 | 2 | 2 |
| 2020 4 | 0 | 3 | 3 |
| 2020 3 | 0 | 7 | 7 |
| 2020 2 | 0 | 4 | 4 |
| 2020 1 | 0 | 5 | 5 |
| 2019 12 | 0 | 7 | 7 |
| 2019 11 | 0 | 1 | 1 |
| 2019 10 | 0 | 2 | 2 |
| 2019 9 | 0 | 2 | 2 |
| 2019 8 | 0 | 4 | 4 |
| 2019 7 | 0 | 6 | 6 |
| 2019 6 | 0 | 10 | 10 |
| 2019 5 | 0 | 45 | 45 |
| 2018 2 | 3 | 4 | 7 |
| 2018 1 | 3 | 0 | 3 |
| 2017 12 | 2 | 5 | 7 |
| 2017 11 | 6 | 5 | 11 |
| 2017 10 | 3 | 7 | 10 |
| 2017 9 | 9 | 15 | 24 |
| 2017 8 | 10 | 3 | 13 |
| 2017 7 | 6 | 2 | 8 |
| 2017 6 | 3 | 20 | 23 |
| 2017 5 | 16 | 15 | 31 |
| 2017 4 | 6 | 12 | 18 |
| 2017 3 | 14 | 44 | 58 |
| 2017 2 | 5 | 4 | 9 |
| 2016 1 | 3 | 7 | 10 |
| 2016 12 | 14 | 7 | 21 |
| 2016 11 | 22 | 6 | 28 |
| 2016 10 | 22 | 5 | 27 |
| 2016 9 | 11 | 9 | 20 |
| 2016 8 | 10 | 3 | 13 |
| 2016 7 | 7 | 2 | 9 |
| 2016 6 | 6 | 7 | 13 |
| 2016 5 | 10 | 10 | 20 |
| 2016 4 | 11 | 19 | 30 |
| 2016 3 | 8 | 9 | 17 |
| 2016 2 | 8 | 18 | 26 |
| 2015 1 | 13 | 12 | 25 |
| 2015 12 | 10 | 7 | 17 |
| 2015 11 | 5 | 3 | 8 |
| 2015 10 | 10 | 4 | 14 |
| 2015 9 | 9 | 4 | 13 |
| 2015 8 | 4 | 5 | 9 |
| 2015 7 | 10 | 1 | 11 |
| 2015 6 | 3 | 2 | 5 |
| 2015 5 | 3 | 4 | 7 |
| 2015 4 | 8 | 7 | 15 |
| 2015 3 | 2 | 1 | 3 |
| 2015 2 | 3 | 1 | 4 |
| 2015 1 | 9 | 2 | 11 |
| 2014 12 | 4 | 4 | 8 |
| 2014 11 | 4 | 4 | 8 |
| 2014 10 | 15 | 2 | 17 |
| 2014 9 | 12 | 1 | 13 |
| 2014 8 | 9 | 1 | 10 |
| 2014 7 | 3 | 1 | 4 |
| 2014 6 | 5 | 3 | 8 |
| 2014 5 | 4 | 1 | 5 |
| 2014 4 | 5 | 3 | 8 |
| 2014 3 | 5 | 2 | 7 |
| 2014 2 | 2 | 1 | 3 |
| 2014 1 | 6 | 1 | 7 |
| 2013 12 | 1 | 2 | 3 |
| 2013 11 | 3 | 2 | 5 |
| 2013 10 | 3 | 2 | 5 |
| 2013 9 | 5 | 6 | 11 |
| 2013 8 | 2 | 1 | 3 |
| 2002 3 | 262 | 0 | 262 |
Mostrar todo
